The Gene Expression Resource (GER) was established with the successful recruitment of Lesleyann Hawthorn, PhD in 2001. The Resource has flourished since that time with a broad base of satisfied users whose continued patronage is derived from a unique approach to microarray experimentation. Its success is largely due to a commitment to provide researchers with high-quality microarray data with the added advantage of data analysis so that the results provided to the individual researchers are in a usable format, unlike most array-based facilities. Dr Hawthorn and the GER staff keep abreast of emerging technologies to provide users with a broad range of expertise and options. This success is substantiated by a large user base, publications and awarded grants. The Resource is functionally divided into Gene Expression, Genotyping, and Copy Number Analysis at the genomics level. At the level of individual chromosomal regions or specific genes, it offers mutation/polymorphism analysis, SNP validation and discovery, expression level quantification and analysis of methylation status. Most importantly, the Resource offers data analysis for all the platforms that it supports and provides expertise, time and funding for the development of novel technologies. For example, Exon array analysis has been developed which allows simultaneous detection of gene expression and alternative splicing events. Furthermore, the Resource is now able to run Whole-Genome Tiling arrays, which permit the highest-resolution Chip-on-Chip analysis as well as the detection of novel transcripts in genomic DNA. During the last few years, the Resource has been working on innovative approaches to the analysis of genomics data. One of these centers on the high-density SNP arrays that offer the highest density genotyping, as well as simultaneous CGH analysis with accompanying LOH analysis. Gene Expression has been using these arrays to look for gains and losses of chromosomal regions (CGH). The ability of the SNP Mapping arrays to detect standard cytogenetic abnormalities represents a major advancement over conventional karyotyping. The GER has collaborated with Dr Cowell's group (GN) to develop statistical analysis tools that permit the overlay of gene expression data with aCGH data, thus enhancing the power of both these technologies. Members of the six CCSG programs utilized this Resource over the last project period. The Resource was instrumental in enhanced peer-reviewed funding, publications and recruitment efforts. It is anticipated that with the new recruitment into the CSBT Program (Dr Gudkov), MTET Program (Dr Adjei), and Til (Dr Lee) the utilization of the Resource will expand. The Resource is used by all six Programs and 98% of users are CCSG members. $80,355 in CCSG support is requested, representing 11% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-36S4
Application #
8637140
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
36
Fiscal Year
2013
Total Cost
$3,763,390
Indirect Cost
$1,467,341
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19

Showing the most recent 10 out of 1555 publications